|
|
 Previous Article | Table of Contents | Next Article 
Phenotypic analysis of human myeloma cell lines
C Duperray, B Klein, BG Durie, X Zhang, M Jourdan, P Poncelet, F Favier, C Vincent, J Brochier and G Lenoir
INSERM U291, SANOFI Recherche, Montpellier, France.
Multiple myeloma (MM) is a B-cell malignancy characterized by the
accumulation, primarily in bone marrow, of a clone of plasma cells. The
nature of the stem cells feeding the tumoral compartment is still unknown.
To investigate this special point, we have studied the phenotypes of nine
well-known human myeloma cell lines (HMCLs) and compared them with those of
normal lymphoblastoid cell lines (LCLs). Twenty-four clusters of
differentiation involved in B lymphopoiesis were investigated using a panel
of 65 monoclonal antibodies (MoAbs). For each cluster, the percentage of
positive cells and the antigen density were determined, giving rise to a
"quantitative phenotype". We thus classified the HMCLs into two different
groups: those with cytoplasmic mu chains (c mu+) and those without (c mu-).
In the first (c mu+) group, comprising seven cell lines, the HMCLs had a
phenotype of pre-B/B cells close to that of Burkitt's lymphoma cell lines.
They expressed low densities of surface mu chains, without detectable
cytoplasmic or surface light chains. Three of them were infected with the
Epstein Barr virus (EBV). These c mu+ HMCLs bore most of the B-cell
antigens except CD23. They expressed the CALLA antigen (CD10) and lacked
the plasma-cell antigen PCA1. In contrast, LCLs expressed surface light
chains, high densities of CD23, low densities of PCA1 antigen, and no CD10
antigen. The c mu- HMCLs had a plasma-cell phenotype, lacking most of the
B-cell antigens and expressing high densities of PCA1 antigen.(ABSTRACT
TRUNCATED AT 250 WORDS)
Volume 73,
Issue 2,
pp. 566-572,
02/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K.-Y. Tsang, C. Palena, J. Gulley, P. Arlen, and J. Schlom
A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1
Clin. Cancer Res.,
March 15, 2004;
10(6):
2139 - 2149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Milazzo, V. L. Reichardt, M. R. Muller, F. Grunebach, and P. Brossart
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA
Blood,
February 1, 2003;
101(3):
977 - 982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-J. Wen, R. Min, G. Tricot, B. Barlogie, and Q. Yi
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
Blood,
May 1, 2002;
99(9):
3280 - 3285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brossart, A. Schneider, P. Dill, T. Schammann, F. Grunebach, S. Wirths, L. Kanz, H.-J. Buhring, and W. Brugger
The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes
Cancer Res.,
September 1, 2001;
61(18):
6846 - 6850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brossart, K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H.-G. Rammensee, L. Kanz, and W. Brugger
Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
Blood,
June 15, 1999;
93(12):
4309 - 4317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, J. A. Mollick, M. Urashima, G. Teoh, D. Chauhan, A. Ogata, N. Raje, J. H.M. Hilgers, L. Nadler, A. R. Belch, et al.
Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone
Blood,
February 15, 1999;
93(4):
1287 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Yi, S. Dabadghao, A. Osterborg, S. Bergenbrant, and G. Holm
Myeloma Bone Marrow Plasma Cells: Evidence for Their Capacity as Antigen-Presenting Cells
Blood,
September 1, 1997;
90(5):
1960 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
